Oncology
-
Multicenter Study Controlled Clinical Trial
Postmarketing surveillance study of OxyContin tablets for relieving moderate to severe cancer pain.
To evaluatethe efficacy and safety of OxyContin tablets (controlled-release oxycodone hydrochloride: 5, 10, 20, and 40 mg) in relieving moderate to severe cancer pain. ⋯ OxyContin tablets demonstrated fast onset of cancer pain control, superior efficacy in relieving both moderate and severe cancer pain and a good safety profile.
-
This is a multicenter investigational survey conducted in 76 hospitals in Shanghai between July and August 2004. The objective was to investigate the cancer pain status and physicians' pain management capabilities in Shanghai. A total of 923 cancer patients involved in the investigation completed a questionnaire which included general condition, self-assessment of pain and questions of pain control knowledge. The study results were analyzed concerning: reason for cancer pain, type and intensity of cancer pain, treatment methods, patients' understanding of addiction, patients' request for pain treatment, and patients' and physicians' viewpoint on current cancer pain treatment.
-
The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) is composed of 5 multi-item function scales and 9 symptom scales. The Korean EORTC QLQ-C30 was drawn up by the EORTC itself. However, its validity and reliability in the palliative care has not been reported. The aim of this study was to evaluate the practicality, reliability, and validity of the Korean EORTC QLQ-C30 in terminally ill patients under cancer pain management. ⋯ Cronbach's alpha coefficient to judge internal consistency was very good except for cognitive functioning. The Korean QLQ-C30 has a strong validity in functional scales. Global quality of life, pain, fatigue, nausea, and sleep disturbance were improved after cancer pain management. These results support that the QLQ-C30 is a reliable and valid measure of quality of life in Korean cancer patients receiving cancer pain management. We consider that the QLQ-C30 can be used effectively in the palliative care settings in order to assess the effects of cancer pain management on quality of life of advanced-stage cancer patients.
-
Multicenter Study
Chemotherapy use and associated factors among cancer patients near the end of life.
We investigated the frequency of chemotherapy use and its associated factors in patients in all age groups in the last year of life. ⋯ Despite the fact that most cancer patients are resistant to chemotherapy at the end of life, it was administered often to all age groups.
-
Randomized Controlled Trial Multicenter Study
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer. Secondary objectives included overall and progression-free survival, duration of response, toxicities, and biomarkers. ⋯ Neither efficacy nor safety improved on the ALIRI arm compared to the FOLFIRI arm. Progression-free survival on FOLFIRI was significantly longer compared to ALIRI. Potential biomarkers capable of predicting response to either regimen in advanced or metastatic colorectal carcinoma need further characterization.